Article
Roche gets a leg up in the anti-TIGIT race with first breakthrough designation for PhII winner tira
Rating:
0.0
Views:
134
Likes:
1
Library:
1
In the race to usher in a next generation of immunotherapies, Roche's Genentech has emerged from the pack, nabbing the first breakthrough designation for an anti-TIGIT drug. The pharma giant's tiragolumab plus Tecentriq landed a spot in the FDA's expedited review program for the first-line treatment of metastatic non-small cell
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value